Literature DB >> 16324086

EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives.

P M Andersen1, G D Borasio, R Dengler, O Hardiman, K Kollewe, P N Leigh, P-F Pradat, V Silani, B Tomik.   

Abstract

Despite being one of the most devastating diseases known, there is little evidence for diagnosing and managing patients with amyotrophic lateral sclerosis (ALS). Although specific therapy is lacking, correct early diagnosis and introduction of symptomatic and specific therapy can have a profound influence on the care and quality of life of the patient and may increase survival time. This document addresses the optimal clinical approach to ALS. The final literature search was performed in the spring of 2005. Consensus recommendations are given graded according to the EFNS guidance regulations. Where there was lack of evidence but consensus was clear we have stated our opinion as good practice points. People affected with possible ALS should be examined as soon as possible by an experienced neurologist. Early diagnosis should be pursued and a number of investigations should be performed with high priority. The patient should be informed of the diagnosis by a consultant with a good knowledge of the patient and the disease. Following diagnosis, the patient and relatives should receive regular support from a multidisciplinary care team. Medication with riluzole should be initiated as early as possible. PEG is associated with improved nutrition and should be inserted early. The operation is hazardous in patients with vital capacity < 50%. Non-invasive positive pressure ventilation improves survival and quality of life but is underused. Maintaining the patients ability to communicate is essential. During the entire course of the disease, every effort should be made to maintain patient autonomy. Advance directives for palliative end of life care are important and should be fully discussed early with the patient and relatives respecting the patients social and cultural background.

Entities:  

Mesh:

Year:  2005        PMID: 16324086     DOI: 10.1111/j.1468-1331.2005.01351.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  61 in total

1.  Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Authors:  John C Morris
Journal:  Arch Neurol       Date:  2012-06

2.  Motor neuron disease: focusing the mind on ALS: updated practice parameters.

Authors:  P Nigel Leigh; Lokesh C Wijesekera
Journal:  Nat Rev Neurol       Date:  2010-04       Impact factor: 42.937

Review 3.  The present and the future of neuroimaging in amyotrophic lateral sclerosis.

Authors:  F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

4.  Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

Authors:  Sarah Jesse; Johannes Brettschneider; Sigurd D Süssmuth; Bernhard G Landwehrmeyer; Christine A F von Arnim; Albert C Ludolph; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2010-12-25       Impact factor: 4.849

5.  ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy.

Authors:  Stefano Zoccolella; Ettore Beghi; Guerrino Palagano; Angela Fraddosio; Vito Guerra; Vito Lepore; Isabella Laura Simone; Paolo Lamberti; Luigi Serlenga; Giancarlo Logroscino
Journal:  J Neurol       Date:  2007-04-13       Impact factor: 4.849

Review 6.  [Amyotrophic lateral sclerosis].

Authors:  R Gastl; A C Ludolph
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

7.  Impairment of GH secretion in amyotrophic lateral sclerosis is not affected by riluzole treatment.

Authors:  L L Morselli; P Bongioanni; M Genovesi; R Licitra; B Rossi; L Murri; F Bogazzi; E Cecconi; E Martino; M Gasperi
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Family health care decision making and self-efficacy with patients with ALS at the end of life.

Authors:  Marie T Nolan; Joan Kub; Mark T Hughes; Peter B Terry; Alan B Astrow; Cynthia A Carbo; Richard E Thompson; Lora Clawson; Kenneth Texeira; Daniel P Sulmasy
Journal:  Palliat Support Care       Date:  2008-09

9.  Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status.

Authors:  Christian Lunetta; Andrea Lizio; Lucio Tremolizzo; Massimiliano Ruscica; Chiara Macchi; Nilo Riva; Patrick Weydt; Ettore Corradi; Paolo Magni; Valeria Sansone
Journal:  J Neurol       Date:  2018-10-22       Impact factor: 4.849

Review 10.  Presymptomatic ALS genetic counseling and testing: Experience and recommendations.

Authors:  Michael Benatar; Christine Stanislaw; Eliana Reyes; Sumaira Hussain; Anne Cooley; Maria Catalina Fernandez; Danielle D Dauphin; Sara-Claude Michon; Peter M Andersen; Joanne Wuu
Journal:  Neurology       Date:  2016-05-18       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.